Pfizer has entered into a definitive agreement to acquire Excaliard Pharmaceuticals, gaining access to EXC 001, a skin scarring treatment.
Co-developed by Excaliard and Isis Pharmaceuticals, EXC 001 is an antisense oligonucleotide that will hinder the process of fibrosis.
A Phase II study of EXC 001 demonstrated positive clinical results in reducing scar severity.
Following the acquisition, Pfizer intends to continue development of EXC 001.
Pfizer will provide Excaliard an upfront payment and contingent payments.
See Also:
The transaction is likely to close by the end of this year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData